PF-5212374
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 exhibits potent direct signaling and antibody-dependent cellular cytotoxicity, with complement-mediated cytotoxicity lower than that of Rituximab. PF-5212374 has antitumor activity and can be used in the research of tumors such as lymphoma and inflammatory diseases[1].
Product Specifications
CAS Number
1169717-01-4
Product Name Alternative
TRU-015
UNSPSC
12352203
Target
CD20
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/pf-5212374-tru-015.html
Purity
97.9
Smiles
[PF-5212374]
References & Citations
[1]Hayden-Ledbetter MS, et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res. 2009 Apr 15;15 (8) :2739-46.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
